Interim report July-September 2022

A challenging third quarter

Quarter July-September 2022

  • Net sales amounted to SEK 125.6 (111.8) million, an increase of 12.4 percent. Adjusted for currency effects, a decrease of -8.1 percent.
  • The number of instruments sold amounted to 803 (996), a decrease by 19.4 percent.
  • Operating profit was SEK 3.6 (13.0) million, corresponding to an operating margin of 2.9 (11.7) percent.
  • Profit for the period amounted to SEK 2.4 (7.1) million.
  • Basic earnings per share amounted to SEK 0.12 (0.37) and diluted earnings per share amounted to SEK 0.12 (0.36).
  • Cash flow from operating activities amounted to SEK -15.8 (10.6) million.
  • Net debt on September 30 amounted to SEK 73.7 million compared to last year when it was SEK 6.5 million.
  • August 4th it was announced that Annette Colin leaves the Boule Diagnostics CFO position due to family reasons.
  • September 6th it was announced that Clinical Diagnostic Solutions, Inc. (CDS), a subsidiary to Boule Diagnostics AB, has been issued a Notice of Inspectional Observations (FDA Form 483) by the US Food and Drug Administration (the FDA).
Key figures Jul-Sep 2022 Jul-Sep 2021 Jan-Sep 2022 Jan-Sep 2021 Oct 21-Sep 22 (R12) Oct 20-Sep 21 (R12)
Sales growth, % 12.4 13.2 23.5 5.0 -4.9 -4.9
Net sales, SEK million 125.6 111.8 398.9 323.1 539.2 415.7
Gross margin, % 40.7 44.7 40.4 43.6 40.6 43.3
Operating profit (EBIT), SEK million 3.6 13.0 18.9 22.2 32.7 -19.5
Operating margin (EBIT), % 2.9 11.7 4.7 6.9 6.1 -4.7
Profit after tax, SEK million 2.4 7.1 9.8 6.0 27.1 -26.6
Net debt, SEK million 73.7 6.5 73.7 6.5 73.7 6.5
Return on equity, % 0.7 2.7 3.1 2.2 8.7 -9.8
Net debt/EBIT (R12), times 2.2 -0.3 2.2 -0.3 2.2 -0.3
Diluted earnings per share, SEK 0.12 0.36 0.49 0.30 1.40 -0.33
Dynamisk graf: Net sales and EBIT, rolling 12 months

Q4 2020 incl. a write-down of intangible assets of SEK 40 million.

 
Latest updated: 11/10/2022 7:47:36 AM by Nils Romberg
NEXT